Hypofractionated FLASH-RT as an Effective Treatment against Glioblastoma that Reduces Neurocognitive Side Effects in Mice.

Details

Serval ID
serval:BIB_228C29969820
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Hypofractionated FLASH-RT as an Effective Treatment against Glioblastoma that Reduces Neurocognitive Side Effects in Mice.
Journal
Clinical cancer research
Author(s)
Montay-Gruel P., Acharya M.M., Gonçalves Jorge P., Petit B., Petridis I.G., Fuchs P., Leavitt R., Petersson K., Gondré M., Ollivier J., Moeckli R., Bochud F., Bailat C., Bourhis J., Germond J.F., Limoli C.L., Vozenin M.C.
ISSN
1557-3265 (Electronic)
ISSN-L
1078-0432
Publication state
Published
Issued date
01/02/2021
Peer-reviewed
Oui
Volume
27
Number
3
Pages
775-784
Language
english
Notes
Publication types: Journal Article ; Comment
Publication Status: ppublish
Abstract
Recent data have shown that single-fraction irradiation delivered to the whole brain in less than tenths of a second using FLASH radiotherapy (FLASH-RT), does not elicit neurocognitive deficits in mice. This observation has important clinical implications for the management of invasive and treatment-resistant brain tumors that involves relatively large irradiation volumes with high cytotoxic doses.
Therefore, we aimed at simultaneously investigating the antitumor efficacy and neuroprotective benefits of FLASH-RT 1-month after exposure, using a well-characterized murine orthotopic glioblastoma model. As fractionated regimens of radiotherapy are the standard of care for glioblastoma treatment, we incorporated dose fractionation to simultaneously validate the neuroprotective effects and optimized tumor treatments with FLASH-RT.
The capability of FLASH-RT to minimize the induction of radiation-induced brain toxicities has been attributed to the reduction of reactive oxygen species, casting some concern that this might translate to a possible loss of antitumor efficacy. Our study shows that FLASH and CONV-RT are isoefficient in delaying glioblastoma growth for all tested regimens. Furthermore, only FLASH-RT was found to significantly spare radiation-induced cognitive deficits in learning and memory in tumor-bearing animals after the delivery of large neurotoxic single dose or hypofractionated regimens.
The present results show that FLASH-RT delivered with hypofractionated regimens is able to spare the normal brain from radiation-induced toxicities without compromising tumor cure. This exciting capability provides an initial framework for future clinical applications of FLASH-RT.See related commentary by Huang and Mendonca, p. 662.
Pubmed
Web of science
Open Access
Yes
Create date
31/10/2020 14:48
Last modification date
06/07/2022 6:35
Usage data